Weijing Sun

14.2k total citations · 4 hit papers
199 papers, 7.9k citations indexed

About

Weijing Sun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Weijing Sun has authored 199 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 46 papers in Surgery. Recurrent topics in Weijing Sun's work include Colorectal Cancer Treatments and Studies (58 papers), Pancreatic and Hepatic Oncology Research (39 papers) and Gastric Cancer Management and Outcomes (36 papers). Weijing Sun is often cited by papers focused on Colorectal Cancer Treatments and Studies (58 papers), Pancreatic and Hepatic Oncology Research (39 papers) and Gastric Cancer Management and Outcomes (36 papers). Weijing Sun collaborates with scholars based in United States, China and South Korea. Weijing Sun's co-authors include Peter J. O’Dwyer, Daniel G. Haller, Ursina Teitelbaum, Robert H. Vonderheide, Babak Saboury, Drew A. Torigian, E. Gabriela Chiorean, Gregory L. Beatty, Dongguang Li and Wenru Song and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Weijing Sun

189 papers receiving 7.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

2011 1.3k citations Gregory L. Beatty, E. Gabriela Chiorean et al. profile →
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

2019 480 citations Weijing Sun et al. profile →
The Role of Angiogenesis in Hepatocellular Carcinoma

2018 417 citations Weijing Sun, Richard S. Finn et al. Clinical Cancer Research profile →
Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer

2020 220 citations Anup Kasi, Saqib Abbasi et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Weijing Sun	4.5k	2.2k	1.7k	1.4k	1.3k	199	7.9k
Robert S. Warren	3.9k 0.9×	3.5k 1.6×	653 0.4×	1.1k 0.8×	1.5k 1.2×	123	8.7k
Mario Scartozzi	3.7k 0.8×	1.7k 0.8×	508 0.3×	2.1k 1.5×	1.5k 1.2×	343	6.4k
Masato Sakon	2.8k 0.6×	3.4k 1.5×	738 0.4×	1.6k 1.1×	1.6k 1.3×	383	9.9k
Zhiqiang Meng	2.4k 0.5×	2.6k 1.2×	639 0.4×	881 0.6×	1.9k 1.5×	148	6.2k
Christopher Stroh	5.6k 1.3×	2.0k 0.9×	525 0.3×	2.5k 1.8×	1.2k 0.9×	78	8.0k
Hal W. Hirte	3.7k 0.8×	3.2k 1.5×	1.0k 0.6×	1.3k 0.9×	977 0.8×	156	8.1k
Muh‐Hwa Yang	2.9k 0.6×	4.0k 1.8×	837 0.5×	990 0.7×	2.2k 1.7×	164	7.6k
Joji Kitayama	2.7k 0.6×	2.9k 1.3×	857 0.5×	1.1k 0.8×	1.4k 1.1×	195	7.4k
Yee Chao	4.6k 1.0×	2.2k 1.0×	1.0k 0.6×	3.9k 2.8×	1.4k 1.2×	344	11.2k
Ryuichiro Doi	4.4k 1.0×	2.9k 1.3×	738 0.4×	1.2k 0.8×	1.1k 0.9×	224	8.3k

Countries citing papers authored by Weijing Sun

Since Specialization

Citations

This map shows the geographic impact of Weijing Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijing Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijing Sun more than expected).

Fields of papers citing papers by Weijing Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weijing Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijing Sun. The network helps show where Weijing Sun may publish in the future.

Co-authorship network of co-authors of Weijing Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Weijing Sun. A scholar is included among the top collaborators of Weijing Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weijing Sun. Weijing Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Weijing, Peijie Li, Ren‐You Pan, et al.. (2025). Global, regional, and national burden of ischemic heart disease in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2021: a systematic analysis of global burden of disease study 2021. Frontiers in Cardiovascular Medicine. 12. 1649408–1649408.

He, Xiang, Weijing Sun, Wenkang Du, Danyang Wang, & Hong Guo. (2025). Fluorescence stress probing enhanced crack detection and quantification in ancient Chinese murals for deterioration mechanism analysis. npj Heritage Science. 13(1).

Kasi, Anup, Milind A. Phadnis, Raed Moh’d Taiseer Al-Rajabi, et al.. (2024). A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).. Journal of Clinical Oncology. 42(3_suppl). TPS719–TPS719. 2 indexed citations

Sun, Weijing, et al.. (2023). Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 24(12). 10230–10230. 20 indexed citations

Saeed, Anwaar, Robin Park, Junqiang Dai, et al.. (2023). Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Reports Medicine. 4(2). 100916–100916. 23 indexed citations

Weng, Shanshan, Chenhan Zhong, Weijing Sun, & Ying Yuan. (2023). Preoperative treatment of locally advanced rectal cancer: less is more. SHILAP Revista de lepidopterología. 4(6). e443–e443. 1 indexed citations

Mehta, Kathan, Raed Moh’d Taiseer Al-Rajabi, Anwaar Saeed, et al.. (2023). Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy. SHILAP Revista de lepidopterología. 4(3). 396–405. 2 indexed citations

Saeed, Anwaar, Robin Park, Junqiang Dai, et al.. (2022). Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal. 1 indexed citations

Kasi, Anup, Jessica L. Allen, Kathan Mehta, et al.. (2021). Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. Journal of Clinical and Translational Research. 7(2). 257–262. 12 indexed citations

10.

Saif, Muhammad Wasif, Carlos Becerra, Marwan Fakih, et al.. (2021). A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemotherapy and Pharmacology. 88(3). 485–497. 6 indexed citations

11.

Mehta, Kathan, et al.. (2020). A prospective testing SARS-Cov-2/COVID-19 in cancer patients with antitumor treatment. Clinical Cancer Research. 26(18). 1 indexed citations

12.

Saeed, Anwaar, Anwaar Saeed, Hannah Hildebrand, et al.. (2020). Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. Journal of Clinical Medicine. 9(9). 2682–2682. 4 indexed citations

13.

Ramamoorthy, Prabhu, Sufi M. Thomas, Gaurav Kaushik, et al.. (2019). Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response. Cancer Research. 79(7). 1681–1695. 44 indexed citations

14.

Saif, Muhammad Wasif, Lee S. Rosen, Michelle A. Rudek, et al.. (2019). Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. British Journal of Clinical Pharmacology. 85(6). 1239–1246. 7 indexed citations

15.

Cong, Liu, Weijing Sun, Ning Li, et al.. (2018). Schisantherin A Improves Learning and Memory of Mice with D-Galactose-Induced Learning and Memory Impairment Through Its Antioxidation and Regulation of p19/p53/p21/Cyclin D1/CDK4/RB Gene Expressions. Journal of Medicinal Food. 21(7). 678–688. 15 indexed citations

16.

Low, Carissa A., Anind K. Dey, Denzil Ferreira, et al.. (2017). Estimation of Symptom Severity During Chemotherapy From Passively Sensed Data: Exploratory Study. Journal of Medical Internet Research. 19(12). e420–e420. 50 indexed citations

17.

Miller, Caitlyn, et al.. (2017). Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. Genes Chromosomes and Cancer. 57(1). 28–34. 2 indexed citations

18.

Sun, Weijing. (2016). Molecular subtypes of colorectal cancer: Evaluation of outcomes and treatment. Oncology and Translational Medicine. 2(4). 145–149. 1 indexed citations

19.

Beatty, Gregory L., Drew A. Torigian, E. Gabriela Chiorean, et al.. (2013). A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 19(22). 6286–6295. 364 indexed citations

20.

Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact